{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-264644","form_type":"8-K","ticker":"STOK","cik":"0001623526","company_name":"Stoke Therapeutics, Inc.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.955962+00:00","generated_at":"2026-05-17T00:38:16.320530+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Stoke Q3 net loss $38.3M ($0.65/sh); Phase 3 EMPEROR >20 randomized","bullets":["Net loss $38.3M ($0.65/sh) vs $26.4M ($0.47) in Q3 2024; revenue $10.6M vs $4.9M.","Cash $328.6M as of Sep 30; $48.7M from Oct share sales; funded to mid-2028.","Phase 3 EMPEROR: >20 patients randomized, ~35 in screening; enrollment on track for H2 2026.","FDA meeting planned before year-end to discuss expedited regulatory pathways for zorevunersen.","Ian F. Smith appointed permanent CEO (was interim); Arthur Tzianabos resumes Chairman role."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-264644","json":"https://secwatch.observer/filing/0001193125-25-264644.json","markdown":"https://secwatch.observer/filing/0001193125-25-264644.md","text":"https://secwatch.observer/filing/0001193125-25-264644.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1623526/000119312525264644/0001193125-25-264644-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1623526/000119312525264644/stok-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:38:16.320530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}